Evaluating the effect of intravenous Paracetamol or Diclofenac Sodium suppositories on the need for intravenous narcotic administration for pain relief in patients underwent stomach surgery

Evaluating the effect of intravenous Paracetamol or Diclofenac Sodium suppositories on the need for intravenous narcotic administration for pain relief in patients underwent gastrectomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112078322N1

Enrollment

Registered

2012-06-02

Start date

2012-06-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric surgery. Acquired absence of part of stomach

Interventions

Intervention 1: Adding intravenous Paracetamol to Morphine PCA in MP group. Intervention 2: Adding Diclofenac Sodium suppositories to Morphine PCA in MD group. Intervention 3: Only Morphine PCA to con

Treatment - Drugs

Adding intravenous Paracetamol to Morphine PCA in MP group

Adding Diclofenac Sodium suppositories to Morphine PCA in MD group

Only Morphine PCA to control group

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Patients with gastric cancer who are candidate for gastrectomy 2. Age range between 40 to70 years 3. Ability to understand PCA pump use Exclusion criteria: 1. History of allergy to morphine, acetaminophen, and diclofenac sodium 2. History of heart failure (EF2), moderate to severe COPD 3. Weight over 10 kilograms or less than 50 kilograms 4. Long-term use of opioids before surgery (for more than 2 weeks continuously)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain intensity. Timepoint: Within the first 24 hours after intervention. Method of measurement: Verbal Analogue Scale.	—

Secondary

Measure	Time frame
Level of Consciousness. Timepoint: Within the first 24 hours after intervention. Method of measurement: Richmond Agitation Sedation Scale (RASS).;Oxygen saturation levels. Timepoint: Within the first 24 hours after intervention. Method of measurement: Pulse oximetry.;Respiratory rate. Timepoint: Within the first 24 hours after intervention. Method of measurement: Counting the number of breaths per minute.;Nausea. Timepoint: Within the first 24 hours after intervention. Method of measurement: Times of nausea and womiting.;Morphine consumption. Timepoint: Within the first 24 hours after intervention. Method of measurement: mg/day.	—

Measure

Time frame

Level of Consciousness. Timepoint: Within the first 24 hours after intervention. Method of measurement: Richmond Agitation Sedation Scale (RASS).;Oxygen saturation levels. Timepoint: Within the first 24 hours after intervention. Method of measurement: Pulse oximetry.;Respiratory rate. Timepoint: Within the first 24 hours after intervention. Method of measurement: Counting the number of breaths per minute.;Nausea. Timepoint: Within the first 24 hours after intervention. Method of measurement: Times of nausea and womiting.;Morphine consumption. Timepoint: Within the first 24 hours after intervention. Method of measurement: mg/day.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Bameshki

Mashhad University of Medical Sciences

bameshkiar@mums.ac.ir; surg.rc@mums.ac.ir+98 51 1802 2677

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026